-
QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., and Guangdong Hengjian Investment Holding Co., Ltd. are jointly selecting a location to launch the Greater Bay Area (GBA) “AI+” technology and industry integration innovation consortium project. The initiative aligns with the national “Innovation Consortium” strategy and aims to integrate…
-
Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in Alternative Bio, alongside an in-depth research partnership with the Wuxi-based biotech firm. Alternative Bio’s Innovative Drug DevelopmentAlternative Bio, founded by three serial entrepreneur scientists, focuses on developing small molecule targeted innovative drugs for major diseases…
-
Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered drug discovery, has announced a multi-million RMB strategic partnership with South Korea’s leading pharmaceutical company, JW Pharmaceutical (KRX: 001060). The collaboration aims to integrate AI and automation into drug discovery, enhancing JW Pharmaceutical’s development efficiency,…
-
Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux’s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were…
-
Xtalpi Inc. Partners with NCCS and Duke-NUS to Advance AI-Driven Drug Discovery
•
Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School. This collaboration will harness the power of artificial intelligence (AI) to revolutionize the discovery and design of clinical drug candidates. AI-Driven Peptide Research…
-
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
•
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with Gnosis Neurodynamics, a leading brain science artificial intelligence (AI) company in China. This collaboration aims to harness AI algorithms and EEG BioMarker recognition models to develop a state-of-the-art neural drug screening platform. The platform will…
-
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
•
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi (QuantumPharm, HKG: 2228). The funds…
-
XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery
•
XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known as QuantumPharm Inc. (HKG: 2228), has announced a significant licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), for its proprietary AI platform, Ailux Biologics’ XtalFold. This platform, recognized…
-
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
•
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.13 billion (USD 144.5 million). The shares of Xtalpi, listed under the ticker symbol 02228, were priced at HKD 6.03 per share. Xtalpi is a pioneer in utilizing quantum physics-based…
-
XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China
•
Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership with Switzerland-based ABB Robotics, aiming to manufacture a series of automated laboratory workstations within China. These workstations, featuring ABB’s GoFa robots, are anticipated to enhance the productivity of R&D processes across biopharmaceuticals, chemical engineering, chemistry,…
-
XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization
•
XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding (MOU) with the Advanced Biomedical Instrumentation Centre (ABIC) at the University of Hong Kong (UHK) to foster collaboration aimed at enhancing research and commercial applications of ABIC’s technological advancements both locally and internationally. Under the…
-
XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a memorandum of understanding (MOU) with the Experimental Drug Development Centre (EDDC) in Singapore to form a collaborative partnership. The two entities have pledged to expand their collaboration to include the application of automated synthesis experiments and large…
-
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis…
-
XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership with US cancer therapy developer Parthenon Therapeutics Inc. to develop antibodies targeting solid tumors. This collaboration aims to leverage the power of AI to advance oncology treatments. Access to XtalPi’s XupremAb Platform and “Experiment+AI” SolutionsUnder…
-
XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership with Edelweiss Connect, a Swiss company specializing in next-generation product design and risk assessment solutions. This collaboration aims to leverage the unique strengths of both companies in chemical and pharmaceutical safety assessment, technology platforms, and market…
-
CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine Ltd and Shenzhen XtalPi (QuantumPharm, HKG: 2228). These collaborations will integrate artificial intelligence (AI) into the field of innovative drug research and development. Under the agreements, CSPC will utilize its drug R&D expertise alongside the…
